Ipsen`s Biologic Dysport (AbobotulinumtoxinA) Receives Approval in the U.S.
Daewoong Pharmaceutical has added benign masseteric hypertrophy (BMH), commonly known as the square jaw, to the indications for its botulinum toxin (BTX) product, Nabota. It is the first case among BTX products worldwide to win the indication for BMH, the company said.
IRVINE, Calif., Aug. 24, 2023 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (œAEON or the œCompany) (NYSE: AEON, AEON WS), a clinical-stage biopharmaceutical company focused on developing a proprietary...
A patent regarding Medytox’s botulinum toxin product can be embroiled in another legal dispute as its domestic rival Hugel filed for a patent invalidation in the US, according to industry sources on Friday.
Ipsen' Biologic DYSPORT (AbobotulinumtoxinA) Receives Approval in the U.S.
Hugel, a global total medical aesthetics company, announced that it resubmitted the BLA for its botulinum toxin called Botulax on October 6th, for the indication of glabellar lines to the US FDA.
The botulinum toxin family of treatments may be best known for aesthetic applications like Botox, but companies have applied them more widely. In Aeon Biopharma's case, its candidate ABP-450 hit its main goals in a phase 2 trial for a rare neck muscle disorder, setting the company up to launch a late-phase study next year.
Galderma has chalked up a pair of phase 3 wins for its liquid formulation botulinum toxin A, positioning it to submit the candidate for approval in the U.S. and other global markets. The formulation is designed to eliminate the need to reconstitute the aesthetic treatment from powder.
SAN DIEGO and CHICAGO, April 1, 2022 /PRNewswire/ -- DelNova, a biopharmaceutical company targeting unmet medical needs, by developing clinically validated molecules linked to advances in drug delivery, announced today that the company is making substantive progress in developing the first ever product to reverse complications arising from administration of botulinum toxin neuromodulators, such as BOTOX®, Dysport®, XEOMIN®, and Jeuveau®. According to the syndicated research firm Fortune Business Insights, the worldwide market for botulinum toxins worldwide is nearly $5 billion and growing steadily; however, potential side effects currently hinder industry growth [https://www.fortunebusinessinsights.com/industry-reports/botulinum-toxin-market-100996]
NEW YORK, March 24, 2022 /PRNewswire/ -- Aquavit Pharmaceuticals, Inc. announced today that it has submitted its IND package (Investigation of New Drug) for a new botulinum toxin (DTX-021) to the FDA for approval.